慢性房颤(CAF)是常见的心律失常,常发生在有心肌缺血、高血压、瓣膜疾病的老年人。Framinghan 20年随访研究表明,有2%居民发生CAF。其死亡率也增加一倍。最近6个独立、双盲、安慰剂对照研究的Meta分析800例服用奎尼丁的CAF患者,较安慰剂组在防止复发上有更好疗效,但死亡危险增加三倍。因而,CAF治疗重点应是长期抗凝,同时控制室率。 CAF患者使用药物控制室率时,常因基础疾病促进药物副作用,导致严重后果,因而使药物选择复 Chronic atrial fibrillation (CAF) is a common arrhythmia, often occurs in the elderly with myocardial ischemia, hypertension, valvular disease. Framinghan 20-year follow-up study showed that 2% of residents had CAF. Its mortality has also doubled. A recent meta-analysis of six independent, double-blind, placebo-controlled studies of 800 CAF patients taking quinidine compared with placebo showed better efficacy in preventing recurrence but a threefold increase in the risk of death. Therefore, CAF treatment should focus on long-term anticoagulation, while controlling room rate. CAF patients with drug control room rate, often due to underlying diseases to promote drug side effects, leading to serious consequences, so that drug selection complex